The San Antonio Breast Cancer Symposium, held annually in the Texas city that is its namesake, attracts thousands of researchers, physicians, health professionals, patient advocates, and others who share the mission of advancing the battle against breast cancer. The symposium provides a critical opportunity for researchers to present their latest findings, learn about the work of other scientists, and share ideas for future studies.
This year's event, which ran from December 9 through 13, drew more than 7,000 attendees from nearly 100 countries and included more than 1,400 research presentations.
Researchers and physicians from the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute comprise a major contingent at each year's symposium. This year, 26 members of the center's faculty were in attendance, presenting research reports and leading educational sessions and career development forums.
Renowned Dana-Farber breast cancer experts shared their discoveries, innovations, and insights from their research and clinical practice with thousands of their fellow oncologists and researchers from around the world.
San Antonio Breast Cancer Symposium 2014 Dana-Farber Participants
Dr. Jennifer Ligibel, breast oncologist at the Susan F. Smith Center for Women's Cancers, discusses promising new treatments for younger HER2+ breast cancer patients.
Beth Overmoyer, MD, breast oncologist at the Susan F. Smith Center for Women’s Cancer's at Dana-Farber, discusses new research she is presenting at the 2014 San Antonio Breast Cancer Symposium on risk factors for Inflammatory Breast Cancer.
Dr. Harold Burstein, breast oncologist at the Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute, shares the latest news from the 2014 San Antonio Breast Cancer Symposium.
Combination of carboplatin and chemotherapy improves outcomes for triple-negative breast cancer patientsIn a clinical trial involving women with triple-negative breast cancer, patients who received the drugs carboplatin and/or bevacizumab in combination with standard chemotherapy prior to surgery were more likely to have their tumors disappear entirely from the breast, according to data presented by investigators during the 2014 San Antonio Breast Cancer Symposium.
Blocking a pathway causing hormonal therapy resistance may benefit women with advanced ER/PR-positive breast cancerAdding a PI3K inhibitor to hormonal therapy for metastatic breast cancer may help overcome resistance to the hormonal therapy and delay disease progression, according to investigators from Dana-Farber Cancer Institute.
In this video, Dr. Eric Winer, Director of Breast Oncology at the Susan F. Smith Center for Women’s Cancers at Dana-Farber, discusses research to be shared by Dana-Farber physician-researchers and their colleagues at the 2014 Breast Cancer Symposium.
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: